Jennifer Macaluso

914 total citations
9 papers, 539 citations indexed

About

Jennifer Macaluso is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jennifer Macaluso has authored 9 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 2 papers in Oncology. Recurrent topics in Jennifer Macaluso's work include Prostate Cancer Treatment and Research (6 papers), Protein Degradation and Inhibitors (6 papers) and Ubiquitin and proteasome pathways (4 papers). Jennifer Macaluso is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Protein Degradation and Inhibitors (6 papers) and Ubiquitin and proteasome pathways (4 papers). Jennifer Macaluso collaborates with scholars based in United States and Germany. Jennifer Macaluso's co-authors include Taavi K. Neklesa, Andrew P. Crew, John Houston, I Taylor, Ryan R. Willard, Jennifer Pizzano, Nicholas Vitale, Caterina Ferraro, Craig M. Crews and Lawrence B. Snyder and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Jennifer Macaluso

9 papers receiving 530 citations

Peers

Jennifer Macaluso

MB

ONCOL

HEMAT

IMMUN

PRM

Ilana Schlam United States

Assunta Melaccio Italy

Haby Henary United States

Mitchell J. Geer United States

Marielle Chiron France

Yasunobu Kuraishi Japan

Arnold Bolomsky Austria

Mark Morrow United States

Max Hallin United States

Jennifer Gauvin United States

Ilana Schlam United States

Jennifer Macaluso

162 ×0.5

MB

324 ×1.9

ONCOL

67 ×0.5

HEMAT

57 ×0.8

IMMUN

142 ×2.3

PRM

Citations per year, relative to Jennifer Macaluso Jennifer Macaluso (= 1×) peers Ilana Schlam

Countries citing papers authored by Jennifer Macaluso

Since Specialization

Citations

This map shows the geographic impact of Jennifer Macaluso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Macaluso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Macaluso more than expected).

Fields of papers citing papers by Jennifer Macaluso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Macaluso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Macaluso. The network helps show where Jennifer Macaluso may publish in the future.

Co-authorship network of co-authors of Jennifer Macaluso

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Macaluso. A scholar is included among the top collaborators of Jennifer Macaluso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Macaluso. Jennifer Macaluso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Snyder, Larry, Taavi K. Neklesa, Xin Chen, et al.. (2023). Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 83(7_Supplement). ND03–ND03. 12 indexed citations

2.

Snyder, Lawrence B., Taavi K. Neklesa, Xin Chen, et al.. (2021). Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 81(13_Supplement). 43–43. 49 indexed citations

3.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2019). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 259–259. 153 indexed citations

4.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations

5.

Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Cancer Research. 78(13_Supplement). 5236–5236. 50 indexed citations

6.

Neklesa, Taavi K., Lawrence B. Snyder, Mark Bookbinder, et al.. (2017). Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer. Cancer Research. 77(13_Supplement). 5637–5637. 2 indexed citations

7.

Currie, Kevin, Jeffrey E. Kropf, Peter Blomgren, et al.. (2014). Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase. Journal of Medicinal Chemistry. 57(9). 3856–3873. 131 indexed citations

8.

Ostendorf, Tammo, Claudia R.C. van Roeyen, Jeffrey D. Peterson, et al.. (2003). A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis. Journal of the American Society of Nephrology. 14(9). 2237–2247. 78 indexed citations

9.

LaRochelle, William J., Michael Jeffers, José R. F. Corvalán, et al.. (2002). Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.. PubMed. 62(9). 2468–73. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact